CoronaryAtlas logo
CoronaryAtlas
Neutrophil gelatinase-associated lipocalin (NGAL)
Pathway / Off-pathway / systemic markers

Neutrophil gelatinase-associated lipocalin (NGAL)

LCN2protein

NGAL is released by activated neutrophils and indicates acute kidney injury and renal dysfunction occurring as a hemodynamic consequence of MI.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleAcute kidney injury marker post-MI; reflects renal stress and systemic hemodynamic consequence, not atherothrombotic cascade mechanistic marker.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000148346

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
100
C — confounder / Type-II
56
A — assay feasibility
68
E — evidence strength
73
T1DI (composite)
36
Specificity differential (R−C)+44
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 3
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 1
6hypertensive emergencymag 1
7high-demand / peri-operative stressmag 2
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Plasma or urine
Collection tube
K2/K3-EDTA (lavender-top) · Sterile urine container
Method / principle
Immunoassay / POC
Reagent / substrate
Anti-NGAL antibody pair
Platform
Automated / POC (Abbott)
Turnaround · availability
Rapid · CE/research

Human genetic evidence

0.026
Open Targets association (STEMI)

Literature evidence(8)

Clinical trials(1)